Neurizon Raises A$2.7m via Entitlement Offer Shortfall to Advance ALS Drug NUZ-001

Pharmaust Limited ( (AU:NUZ) ) has provided an update.

Neurizon Therapeutics has secured firm commitments to raise about A$2.7 million via a placement of shortfall shares from its recent non-renounceable entitlement offer, lifting total proceeds from the offer to roughly A$8.5 million. The placement, backed by new and existing sophisticated investors, will see 33.2 million new shares issued at A$0.08, with settlement and allotment due in late April and the shares ranking equally with existing stock.

The fresh capital strengthens Neurizon’s balance sheet and provides additional flexibility to fund the Phase 2/3 clinical development and commercialisation plans for its lead asset NUZ-001, as well as general working capital. Management highlighted that the company remains funded to participate in the HEALEY ALS Platform Trial and is maintaining a disciplined capital strategy aligned with its clinical and regulatory milestones, supporting its positioning in the competitive ALS therapeutics landscape.

The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.28 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.

More about Pharmaust Limited

Neurizon Therapeutics Limited is an ASX- and OTCQB-listed clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative diseases, particularly amyotrophic lateral sclerosis, the most common form of motor neurone disease. Its lead investigational drug candidate, NUZ-001, is being advanced through international collaborations and rigorous clinical programs, with potential applications across broader neurodegenerative indications.

Average Trading Volume: 566,723

Technical Sentiment Signal: Sell

Current Market Cap: A$58.84M

Find detailed analytics on NUZ stock on TipRanks’ Stock Analysis page.